Founded Year
1999Stage
Acquired | AcquiredAbout e-vita
e-vita AS provides IT solutions for optimizing business processes and is a provider in Norway in portals and process solutions based on technology from Oracle. The company is also a specialized partner for databases and application grids. In addition, e-vita provides consulting services with expertise in the user experience, project management, system integration and administration.
e-vita Headquarter Location
Stortorvet 10
Oslo, NO-0155,
Norway
478 70 097
e-vita Patents
e-vita has filed 1 patent.
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
4/27/2010 | 4/22/2014 | Sensors, Biosensors, Biotechnology, Gas sensors, Transducers | Grant |
Application Date | 4/27/2010 |
---|---|
Grant Date | 4/22/2014 |
Title | |
Related Topics | Sensors, Biosensors, Biotechnology, Gas sensors, Transducers |
Status | Grant |
Latest e-vita News
Mar 6, 2020
March 6th, 2020 CryoLife, Inc., a company based outside of Atlanta, Georgia, announced this week that it has received the European CE Mark for the E-vita Open NEO, a hybrid stent graft system for the treatment of aortic arch disease. Aortic arch disease encompasses both aortic aneurysms and aortic dissections, which occur suddenly and could be fatal. According to the release, about 7,000 patients are treated surgically for aortic arch disease annually in Europe, the Middle East, and Africa. Many patients with either an aneurysm or dissection in the aortic arch also present with a dissected or aneurysmal descending thoracic aorta. Often, these two conditions are addressed in a two-stage repair – one to repair the arch and the next to repair the descending thoracic aorta. CryoLife’s E-vita Open NEO enables surgeons to combine these two procedures into one, which allows patients to avoid a second surgery and provides a more cost-effective solution for hospitals. It is anticipated that the E-vita Open NEO will often be used in combination with JOTEC’s thoracic stent graft offering, E-nya. “We are pleased to have received CE Mark for E-vita Open NEO™, our newest hybrid stent graft technology for aortic arch and descending thoracic aorta repair,” said Pat Mackin, Chairman, President, and CEO of CryoLife, in a press statement. “This new design features a single tri-branched vessel that enhances ease-of-use and implantation that reduces surgical time and allows for a potentially safer procedure, thereby increasing the likelihood that more patients can benefit from the procedure and patient access to these therapies.”
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.